Merck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review
Dateline City:
KENILWORTH, N.J.
ZEPATIER Achieves High Cure Rates (SVR12) in Broad Range of Patients with Chronic Hepatitis C Infection, Including Those with Compensated Cirrhosis, Renal Impairment of Any Degree and HIV-1/HCV Co-infection
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved ZEPATIERâ„¢ (elbasvir and grazoprevir) for the
treatment of adult patients with chronic hepatitis C virus (HCV)
genotype (GT) 1 or GT4 infection, with or without ribavirin (RBV),
following priority review by the FDA.
Language:
English
Contact:
MerckMedia:Doris Li, 908-246-5701Sarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Hepatitis NYSE:MRK Source Type: news
More News: Cirrhosis | Food and Drug Administration (FDA) | Hepatitis | Hepatitis C | Merck | Pharmaceuticals